Trevi Therapeutics (TRVI) Cash from Operations (QoQ) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -118.70% |
| Dec 31, 2025 | 29.86% |
| Sep 30, 2025 | -7.71% |
| Jun 30, 2025 | 25.05% |
| Mar 31, 2025 | -41.12% |
| Dec 31, 2024 | 0.06% |
| Sep 30, 2024 | -10.05% |
| Jun 30, 2024 | 17.04% |
| Mar 31, 2024 | -64.60% |
| Dec 31, 2023 | 12.64% |
| Sep 30, 2023 | 26.29% |
| Jun 30, 2023 | -20.47% |
| Mar 31, 2023 | -29.47% |
| Dec 31, 2022 | 26.18% |
| Sep 30, 2022 | -38.86% |
| Jun 30, 2022 | 12.92% |
| Mar 31, 2022 | -13.85% |
| Dec 31, 2021 | 13.98% |
| Sep 30, 2021 | 8.32% |
| Jun 30, 2021 | -4.22% |
| Mar 31, 2021 | 15.08% |
| Dec 31, 2020 | -28.09% |
| Sep 30, 2020 | 17.41% |
| Jun 30, 2020 | -80.53% |
| Mar 31, 2020 | 24.65% |
| Dec 31, 2019 | 19.81% |
| Sep 30, 2019 | -52.82% |
| Jun 30, 2019 | -23.56% |
| Mar 31, 2019 | 13.44% |
| Dec 31, 2018 | -18.51% |
| Sep 30, 2018 | 28.82% |
| Jun 30, 2018 | -41.88% |